Adverse Drug Reactions and Fouad Namouni

Selected news for the healthcare topic - Adverse Drug Reactions, and the person - Fouad Namouni. We have 5 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
9/5/2019 Bristol-Myers Squibb Provides Update on Phase 3 Opdivo (nivolumab) CheckMate -548 Trial in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme | Business & Finance | heraldchronicle.com Business Wire ... aggressive and difficult disease to treat. We look forward to seeing the overall survival data when they are available,” said Fouad Namouni, M.D., head, Oncology Development, Bristol-Myers Squibb. “We are grateful to the patients ... patients receiving OPDIVO. The most frequent Grade 3 and 4 adverse drug reactions reported in 2% to 5% of patients receiving OPDIVO were abdominal pain, hyponatremia, increased aspartate aminotransferase, and increased lipase. In Checkmate 066 ...
11/12/2017 First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017 PR Newswire ... These initial findings underscore the potential benefit of the combination of Opdivo and NKTR-214 across several tumor types," said Fouad Namouni, M.D., Head of Oncology Development, Bristol-Myers Squibb. "We believe that a combination ... patients receiving OPDIVO. The most frequent Grade 3 and 4 adverse drug reactions reported in 2% to 5% of patients receiving OPDIVO were abdominal pain, hyponatremia, increased aspartate aminotransferase, and increased lipase. In Checkmate 066 ...
11/12/2017 First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV PR Newswire ... These initial findings underscore the potential benefit of the combination of Opdivo and NKTR-214 across several tumor types," said Fouad Namouni, M.D., Head of Oncology Development, Bristol-Myers Squibb. "We believe that a combination ... patients receiving OPDIVO. The most frequent Grade 3 and 4 adverse drug reactions reported in 2% to 5% of patients receiving OPDIVO were abdominal pain, hyponatremia, increased aspartate aminotransferase, and increased lipase. In Checkmate 066 ...
11/11/2017 First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017 PR Newswire ... These initial findings underscore the potential benefit of the combination of Opdivo and NKTR-214 across several tumor types," said Fouad Namouni, M.D., Head of Oncology Development, Bristol-Myers Squibb. "We believe that a combination ... patients receiving OPDIVO. The most frequent Grade 3 and 4 adverse drug reactions reported in 2% to 5% of patients receiving OPDIVO were abdominal pain, hyponatremia, increased aspartate aminotransferase, and increased lipase. In Checkmate 066 ...
11/9/2017 Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors | Business Wire Business Wire ... on discovering ways to leverage the complex tumor microenvironment to help restore the body’s natural ability to fight cancer,” said Fouad Namouni, M.D., head of development, Oncology, Bristol-Myers Squibb. “These preliminary results support our ... patients receiving OPDIVO . The most frequent Grade 3 and 4 adverse drug reactions reported in 2% to 5% of patients receiving OPDIVO were abdominal pain, hyponatremia, increased aspartate aminotransferase, and increased lipase. In Checkmate 066 ...
11/9/2017 Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors | Business Wire Business Wire ... on discovering ways to leverage the complex tumor microenvironment to help restore the body’s natural ability to fight cancer,” said Fouad Namouni, M.D., head of development, Oncology, Bristol-Myers Squibb. “These preliminary results support our ... patients receiving OPDIVO . The most frequent Grade 3 and 4 adverse drug reactions reported in 2% to 5% of patients receiving OPDIVO were abdominal pain, hyponatremia, increased aspartate aminotransferase, and increased lipase. In Checkmate 066 ...
11/7/2017 Bristol-Myers Squibb to Highlight Clinical and Translational Research at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting | Business Wire Business Wire ... investigate novel mechanisms to address areas of high unmet need, with the goal of establishing new standards of care,” said Fouad Namouni, M.D., head of development, Oncology, Bristol-Myers Squibb. “Through our research initiatives and ... patients receiving OPDIVO . The most frequent Grade 3 and 4 adverse drug reactions reported in 2% to 5% of patients receiving OPDIVO were abdominal pain, hyponatremia, increased aspartate aminotransferase, and increased lipase. In Checkmate 066 ...